U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H11ClF3N3O2S
Molecular Weight 401.791
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SC-236

SMILES

NS(=O)(=O)C1=CC=C(C=C1)N2N=C(C=C2C3=CC=C(Cl)C=C3)C(F)(F)F

InChI

InChIKey=NSQNZEUFHPTJME-UHFFFAOYSA-N
InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

HIDE SMILES / InChI
Molecular Formula C16H11ClF3N3O2S
Molecular Weight 401.791
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22264485 | https://www.ncbi.nlm.nih.gov/pubmed/24125884

SC 26196 is a selective delta6 fatty acid desaturase inhibitor with anti-inflammatory and anti-cancer properties.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 5.0 nM [EC50]
Agonist
2752
 58.0 nM [EC50]
Agonist
2752
 17.0 nM [EC50]
Prostaglandin G/H synthase 2
51
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.005 µM [IC50]
Transcription factor AP-1
4
Target ID: P05412
Gene ID: 3725.0
Gene Symbol: JUN
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 25.0 µM [IC50]
Fatty acid desaturase 2
9
Target ID: O95864
Gene ID: 9415.0
Gene Symbol: FADS2
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.2 µM [IC50]
Leukotriene A-4 hydrolase
6
Target ID: P09960
Gene ID: 4048.0
Gene Symbol: LTA4H
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 2.5 nM [IC50]
Prostaglandin G/H synthase 2
51
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.05 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of delta-6 desaturase reverses cardiolipin remodeling and prevents contractile dysfunction in the aged mouse heart without altering mitochondrial respiratory function.
2014-07
Modulators of the Sphingosine 1-phosphate receptor 1.
2013-12-01
Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
2012-05
Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist.
2012-02-15
Degradation of methamidophos by Hyphomicrobium species MAP-1 and the biochemical degradation pathway.
2010-07
Conjugated linoleic acid-induced fat loss dependence on Delta6-desaturase or cyclooxygenase.
2008-10
Insoluble zinc, cupric and tin pyrophosphates inhibit the formation of volatile sulphur compounds.
2004-10
Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase.
2004-01
Effect of the delta6-desaturase inhibitor SC-26196 on PUFA metabolism in human cells.
2003-04
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
2002-12-02
Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies.
2002-02
Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
2002-02
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas.
2002-01
Gas production by feces of infants.
2001-05
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
2001-03-18
Function of gingival fibroblasts and periodontal ligament cells in the presence of methyl mercaptan.
1999-05
Differentiation of mouth versus gut as site of origin of odoriferous breath gases after garlic ingestion.
1999-02
Failure of activated charcoal to reduce the release of gases produced by the colonic flora.
1999-01
Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.
1998-10
Neonatal encephalopathy with a pungent body odour.
1997-07
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
1997-04-25
Isolation and identification of metabolites of leukotriene A4 hydrolase inhibitor SC-57461 in rats.
1996-10
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.
1996-06-28
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
1996-06-01
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
1994-12-06
Volatile sulfur compounds in mouth air from clinically healthy subjects and patients with periodontal disease.
1992-07
Enzymatic methylation of sulfide, selenide, and organic thiols by Tetrahymena thermophila.
1987-09
Widespread occurrence of bacterial thiol methyltransferases and the biogenic emission of methylated sulfur gases.
1987-07
Suicide inactivation of bacterial cystathionine gamma-synthase and methionine gamma-lyase during processing of L-propargylglycine.
1979-10-16
Development of specific tests for rapid detection of Escherichia coli and all species of Proteus in urine.
1977-09
The antituberculous activity of ethyl mercaptan.
1956-07
Patents

Patents

03950429
4
03963734
8
03966965
5
03968116
4
03974222
4
03978116
11
04001419
7
04045559
4
04052393
4
04065560
8
04087432
4
04089960
4
04115575
10
04138410
12
04154936
4
04160100
5
04171361
6
04175199
4
04179508
4
04206121
4
04236002
8
04268514
7
04308208
9
04340740
12
04379819
4
04427589
5
04442109
4
04447435
4
04469634
4
04478835
4
04548750
4
04567283
4
04603201
5
04604466
4
04689072
7
04746352
6
04760163
4
04788185
4
04810282
5
04814332
5
04886835
7
04927939
4
04935413
4
04971979
7
04971982
4
05001243
4
05051508
6
05057614
5
05064844
5
05194650
4
05240924
6
06528232
4
07399893
5
EP0731793
4
US5585492
4
WO9515315
4
WO9610999
4
WO9611192
4
WO9641625
4

Sample Use Guides

In Vivo Use Guide
0.1, 0.3, 1, or 3 mg/kg from day 0 to day 17, once daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Tue Apr 01 23:58:24 GMT 2025
Edited
by admin
on Tue Apr 01 23:58:24 GMT 2025
Record UNII
9HGW1H8S2M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SC-236
Code English
4-(5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE
Preferred Name English
BENZENESULFONAMIDE, 4-(5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)-
Systematic Name English
Code System Code Type Description
DRUG BANK
DB14059
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
FDA UNII
9HGW1H8S2M
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
SMS_ID
300000017496
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
EPA CompTox
DTXSID80432082
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
CAS
170569-86-5
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
PUBCHEM
9865808
Created by admin on Tue Apr 01 23:58:24 GMT 2025 , Edited by admin on Tue Apr 01 23:58:24 GMT 2025
PRIMARY
Related Record Type Details
COX-2
TARGET -> INHIBITOR
Related Record Type Details
Structure of SC-236
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966